Inhibitor Therapeutics, Inc. (INTI): R&D Expense
$1.70M
Year ended 2025-12-31
$1.70M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.70M | -3.5% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $1.76M | n/c | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $1.38M | n/m | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $6.2K | +25.4% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $4.9K | -97.4% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $185.3K | -84.7% | 2022-03-30, From 2020-01-01 |
| 2019-12-31 | $1.21M | -54.1% | 2021-03-26, From 2019-01-01 |
| 2018-12-31 | $2.63M | +18.2% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $2.23M | -15.7% | 2019-03-07, From 2017-01-01 |
| 2016-12-31 | $2.64M | +57.2% | 2018-02-16, From 2016-01-01 |
| 2015-12-31 | $1.68M | -30.9% | 2017-02-17, From 2015-01-01 |
| 2014-12-31 | $2.43M | +128.2% | 2016-02-01, From 2014-01-01 |
| 2013-12-31 | $1.07M | n/a | 2015-02-13, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Inhibitor Therapeutics, Inc. (INTI) | 2025-12-31 | $1.70M | -3.5% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $12.54M | -24.3% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $3.61M | +18.9% |
| Artelo Biosciences, Inc. (ARTL) | 2025-12-31 | $5.42M | -9.5% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $1.80M | -19.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.36M | +276.5% |
| InMed Pharmaceuticals Inc. (INM) | 2026-06-30 | $3.03M | +7.3% |
Compare INTI, VCNX, LIPO, ARTL side by side · Screen every company in Pharmaceutical Preparations ↗